SEC Form 4 · accession 0000899243-18-003131
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Anastasios Gianakakos
Officer — President and CEO · Director
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 6:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2018 | M | 3,000 | $1.5068 | A | 77,390 | D | |
| Common StockF2 | Feb 5, 2018 | S | 954 | $49.7806 | D | 76,436 | D | |
| Common StockF3 | Feb 5, 2018 | S | 699 | $50.9109 | D | 75,737 | D | |
| Common StockF4 | Feb 5, 2018 | S | 1,147 | $51.9151 | D | 74,590 | D | |
| Common StockF5 | Feb 5, 2018 | S | 200 | $52.575 | D | 74,390 | D | |
| Common StockF1 | holding | — | — | — | 12,200 | I | By The Alexander Gianakakos 2015 Irrevocable Trust dtd 9/26/2015 | |
| Common StockF1 | holding | — | — | — | 12,200 | I | By The Emmanuel Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 | |
| Common StockF1 | holding | — | — | — | 12,200 | I | By The James Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 | |
| Common Stock | holding | — | — | — | 85,973 | I | By The Gianakakos Family Revocable Trust DTD 11/02/2006 | |
| Common Stock | holding | — | — | — | 500,000 | I | By The Tassos Gianakakos 2018 Annuity Trust dtd 1/6/2018 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $1.5068 | Feb 5, 2018 | M | 3,000 | D | — | Jun 3, 2025 | Common Stock | 3,000 | 137,235 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Represents the weighted average sale price of the shares sold ranging from $49.35 to $50.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sale price of the shares sold ranging from $50.50 to $51.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sale price of the shares sold ranging from $51.50 to $52.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sale price of the shares sold ranging from $52.50 to $52.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F625% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019.